Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia

J. Z. Gong, H. Zhou, Z. Hu, P. Schulman, V. Vinceguerra, J. D. Broome, P. Koduru

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

p21 is induced by and mediates the effects of p53 in response to DNA damage arresting the cell in G1 or G2, by inhibiting multiple cyclin-cyclin-dependent kinases (CDK) or binding to proliferating-cell nuclear antigen (PCNA), respectively. To determine whether p21 mutants occur in tumors we examined DNA from 188 primary non-Hodgkin's B-cell lymphoma (NHL) tumors and 84 chronic myelogenous leukemia samples for mutational changes in the coding region of p21 by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of polymerase chain reaction (PCR)-amplified DNA. We did not find mutations in the coding region in these two tumor types. We identified a polymorphic nucleotide change in codon 31 in which a transversion from C to A substituted amino acid arginine for serine. Three of 188 NHL tumors were homozygous for this change, but they were nor identified in 84 CMLs or in 97 normal controls. On the other hand, in one CML case a transition from G to A in codon 64 substituted amino acid threonine for alanine. These data do not indicate that derangements in the coding region of p21 contribute to the initiation and/or progression of these tumors.

Original languageEnglish (US)
Pages (from-to)171-177
Number of pages7
JournalHematologic Pathology
Volume9
Issue number3-4
StatePublished - 1995

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Non-Hodgkin's Lymphoma
Genes
Neoplasms
Codon
Amino Acids
Cyclins
Cyclin-Dependent Kinases
DNA
Proliferating Cell Nuclear Antigen
B-Cell Lymphoma
Threonine
Alanine
Serine
DNA Damage
Arginine
Nucleotides
Polymerase Chain Reaction
Mutation

ASJC Scopus subject areas

  • Hematology
  • Pathology and Forensic Medicine

Cite this

Gong, J. Z., Zhou, H., Hu, Z., Schulman, P., Vinceguerra, V., Broome, J. D., & Koduru, P. (1995). Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. Hematologic Pathology, 9(3-4), 171-177.

Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. / Gong, J. Z.; Zhou, H.; Hu, Z.; Schulman, P.; Vinceguerra, V.; Broome, J. D.; Koduru, P.

In: Hematologic Pathology, Vol. 9, No. 3-4, 1995, p. 171-177.

Research output: Contribution to journalArticle

Gong, JZ, Zhou, H, Hu, Z, Schulman, P, Vinceguerra, V, Broome, JD & Koduru, P 1995, 'Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia', Hematologic Pathology, vol. 9, no. 3-4, pp. 171-177.
Gong JZ, Zhou H, Hu Z, Schulman P, Vinceguerra V, Broome JD et al. Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. Hematologic Pathology. 1995;9(3-4):171-177.
Gong, J. Z. ; Zhou, H. ; Hu, Z. ; Schulman, P. ; Vinceguerra, V. ; Broome, J. D. ; Koduru, P. / Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. In: Hematologic Pathology. 1995 ; Vol. 9, No. 3-4. pp. 171-177.
@article{c10a63dbdced45a6805494eacc036c04,
title = "Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia",
abstract = "p21 is induced by and mediates the effects of p53 in response to DNA damage arresting the cell in G1 or G2, by inhibiting multiple cyclin-cyclin-dependent kinases (CDK) or binding to proliferating-cell nuclear antigen (PCNA), respectively. To determine whether p21 mutants occur in tumors we examined DNA from 188 primary non-Hodgkin's B-cell lymphoma (NHL) tumors and 84 chronic myelogenous leukemia samples for mutational changes in the coding region of p21 by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of polymerase chain reaction (PCR)-amplified DNA. We did not find mutations in the coding region in these two tumor types. We identified a polymorphic nucleotide change in codon 31 in which a transversion from C to A substituted amino acid arginine for serine. Three of 188 NHL tumors were homozygous for this change, but they were nor identified in 84 CMLs or in 97 normal controls. On the other hand, in one CML case a transition from G to A in codon 64 substituted amino acid threonine for alanine. These data do not indicate that derangements in the coding region of p21 contribute to the initiation and/or progression of these tumors.",
author = "Gong, {J. Z.} and H. Zhou and Z. Hu and P. Schulman and V. Vinceguerra and Broome, {J. D.} and P. Koduru",
year = "1995",
language = "English (US)",
volume = "9",
pages = "171--177",
journal = "Hematologic Pathology",
issn = "0886-0238",
publisher = "Marcel Dekker Inc.",
number = "3-4",

}

TY - JOUR

T1 - Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia

AU - Gong, J. Z.

AU - Zhou, H.

AU - Hu, Z.

AU - Schulman, P.

AU - Vinceguerra, V.

AU - Broome, J. D.

AU - Koduru, P.

PY - 1995

Y1 - 1995

N2 - p21 is induced by and mediates the effects of p53 in response to DNA damage arresting the cell in G1 or G2, by inhibiting multiple cyclin-cyclin-dependent kinases (CDK) or binding to proliferating-cell nuclear antigen (PCNA), respectively. To determine whether p21 mutants occur in tumors we examined DNA from 188 primary non-Hodgkin's B-cell lymphoma (NHL) tumors and 84 chronic myelogenous leukemia samples for mutational changes in the coding region of p21 by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of polymerase chain reaction (PCR)-amplified DNA. We did not find mutations in the coding region in these two tumor types. We identified a polymorphic nucleotide change in codon 31 in which a transversion from C to A substituted amino acid arginine for serine. Three of 188 NHL tumors were homozygous for this change, but they were nor identified in 84 CMLs or in 97 normal controls. On the other hand, in one CML case a transition from G to A in codon 64 substituted amino acid threonine for alanine. These data do not indicate that derangements in the coding region of p21 contribute to the initiation and/or progression of these tumors.

AB - p21 is induced by and mediates the effects of p53 in response to DNA damage arresting the cell in G1 or G2, by inhibiting multiple cyclin-cyclin-dependent kinases (CDK) or binding to proliferating-cell nuclear antigen (PCNA), respectively. To determine whether p21 mutants occur in tumors we examined DNA from 188 primary non-Hodgkin's B-cell lymphoma (NHL) tumors and 84 chronic myelogenous leukemia samples for mutational changes in the coding region of p21 by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of polymerase chain reaction (PCR)-amplified DNA. We did not find mutations in the coding region in these two tumor types. We identified a polymorphic nucleotide change in codon 31 in which a transversion from C to A substituted amino acid arginine for serine. Three of 188 NHL tumors were homozygous for this change, but they were nor identified in 84 CMLs or in 97 normal controls. On the other hand, in one CML case a transition from G to A in codon 64 substituted amino acid threonine for alanine. These data do not indicate that derangements in the coding region of p21 contribute to the initiation and/or progression of these tumors.

UR - http://www.scopus.com/inward/record.url?scp=0028792348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028792348&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 171

EP - 177

JO - Hematologic Pathology

JF - Hematologic Pathology

SN - 0886-0238

IS - 3-4

ER -